West Pharmaceutical Services (WST) Financial History
Review West Pharmaceutical Services annual and quarterly financial results, key ratios, insider transactions and SEC filing history in one chronological view. Data available from FY2008 through FY2025.
Financials
18 fiscal years, FY2008 to FY2025
Insider trades
361 trades
Risk factor changes
16 changes in the latest 10-K
Filings
Annual and quarterly reports
Compare
Side by side with another company
West Pharmaceutical Services Financial Statements
History since FY2008. Annual, in US dollars. Source: 10-K XBRL data.
West Pharmaceutical Services Revenue and Growth
Compare reported revenue and year-over-year revenue growth across available fiscal years.
West Pharmaceutical Services Income Statements
Review revenue, gross profit, operating income, net income and earnings per share.
West Pharmaceutical Services Balance Sheets
Review reported debt and book-value-based ratios where company data is available.
West Pharmaceutical Services Cash Flow Statements
Compare reported free cash flow across the available fiscal history.
West Pharmaceutical Services Financial Ratios
Compare net margin, price-to-earnings and price-to-book ratios by fiscal year.
| Fiscal year | FY2008 🔒 | FY2009 🔒 | FY2010 🔒 | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $2.8B | $2.9B | $2.9B | $2.9B | $3.1B |
| Revenue growth | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | — | +2.0% | +2.2% | -1.9% | +6.3% |
| Gross profit | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $1.2B | $1.1B | $1.1B | $1.0B | $1.1B |
| Operating income | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $0.8B | $0.7B | $0.7B | $0.6B | $0.6B |
| Net income | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $0.7B | $0.6B | $0.6B | $0.5B | $0.5B |
| Debt | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $0.3B | $0.2B | $0.2B | $0.2B | $0.2B |
| Free cash flow | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $0.3B | $0.4B | $0.4B | $0.3B | $0.5B |
| Net margin | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
| EPS (diluted) | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 |
| P/E ratio | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 54.1× | 30.4× | 44.7× | 49.0× | 40.5× |
| P/B ratio | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 14.9× | 6.5× | 9.0× | 8.8× | 6.2× |
Daily closing prices, aggregated by calendar year.
| Year | 2000 🔒 | 2001 🔒 | 2002 🔒 | 2003 🔒 | 2004 🔒 | 2005 🔒 | 2006 🔒 | 2007 🔒 | 2008 🔒 | 2009 🔒 | 2010 🔒 | 2011 🔒 | 2012 🔒 | 2013 🔒 | 2014 🔒 | 2015 🔒 | 2016 🔒 | 2017 🔒 | 2018 🔒 | 2019 🔒 | 2020 🔒 | 2021 🔒 | 2022 | 2023 | 2024 | 2025 | 2026 (YTD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Open | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $465.51 | $238.31 | $351.97 | $328.90 | $275.52 |
| Close | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $235.30 | $352.24 | $327.61 | $275.21 | $392.32 |
| High | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $466.67 | $415.67 | $413.75 | $348.24 | $445.82 |
| Low | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $206.19 | $226.22 | $266.22 | $187.50 | $223.85 |
| Annual return | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | -49.8% | +49.7% | -7.0% | -16.0% | +42.5% |
West Pharmaceutical Services Insider Transactions
From Form 4 filings. Showing the latest 5 of 361 trades.
| Traded | Filed | Insider | Type | Shares | Value | % of holdings |
|---|---|---|---|---|---|---|
| 2026-09-30 | 2026-10-02 | Janet Brutschea Haugen Director | Grant or award | 44 | $16K | — |
| 2026-09-11 | 2026-09-15 | Annette Favorite Sr. VP & Chief HR Officer | Option exercise (7 trades) | 17,500 | $224K | — |
| 2026-09-14 | 2026-09-15 | Annette Favorite Sr. VP & Chief HR Officer | Option exercise (7 trades) | 17,500 | $224K | — |
| 2026-09-15 | 2026-09-15 | Annette Favorite Sr. VP & Chief HR Officer | Option exercise (7 trades) | 17,668 | $226K | — |
| 2026-09-11 | 2026-09-15 | Annette Favorite Sr. VP & Chief HR Officer | Sold | 2,500 | $863K at ~$345 | — |
West Pharmaceutical Services Risk Factor Changes
Latest 10-K compared with the year before. 16 changes found.
The manufacturing of some of our products has involved, and may continue to involve, the use, transportation, storage, and disposal of hazardous or toxic materials and is subject to various environmental protection an…
Many of our customers are subject to the same or related emerging legislation or regulations and, as a result, may request that changes be made to our products, procedures or facilities, as well as other aspects of ou…
We believe it is likely that the scientific and political attention to issues concerning the extent and causes of climate change will continue, with new and more restrictive legislation or regulations and focus on cli…
Our future success depends, in large part, on our ability to attract and retain key employees, including our executive officers and individuals in technical, marketing, sales, and research positions.
We may not succeed in completing divestitures, acquisitions or other strategic transactions, all of which could have an adverse effect on our business and results of operations.
The medical technology industry is very competitive and customer requests and/or new products in the marketplace could cause a reduction in demand.
Our business depends to a substantial extent on customers’ continued sales and development of products that are delivered by injection, such as GLP-1s.
A significant portion of our net sales and earnings are generated internationally.
Global economic conditions, including inflation and supply chain disruptions, could adversely affect our operations.
As of the filing of this Form 10-K, there were no unresolved comments from the Staff of the SEC.
Effective internal controls are necessary for us to provide reliable and accurate financial statements and to effectively prevent fraud.
If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results, which could lead to a loss of investor confidence in our financial statements and have an…
We derive a substantial portion of our revenue from a limited number of customers.
The concentration of our customer base could adversely affect our financial condition and operating results.
With respect to divestitures or dispositions, we continually assess the strategic fit of our existing businesses and products and may divest or otherwise dispose of businesses or products for strategic, financial or o…
In the normal course of business, we engage in discussions with third parties relating to possible divestitures, acquisitions and other strategic transactions.
West Pharmaceutical Services SEC Filings
Latest annual and quarterly reports, current reports, proxy statements and ownership filings.
| Form | Filed | Description | Document |
|---|---|---|---|
| Ownership change (13D/13G) amendment | 2026-11-05 | Large shareholder report (5% or more) | View document |
| Quarterly report (10-Q) | 2026-10-29 | Quarter ended Sep 30, 2026 | View document |
| Current report (8-K) | 2026-10-29 | Quarterly results, Company update | View document |
| Current report (8-K) | 2026-10-26 | Material agreement, Agreement ended | View document |
| Ownership change (13D/13G) | 2026-08-06 | Large shareholder report (5% or more) | View document |
West Pharmaceutical Services financial metrics by year
Compare West Pharmaceutical Services with similar companies
- WST vs BAX Baxter International
- WST vs BDX Becton Dickinson
- WST vs BSX Boston Scientific
- WST vs DXCM Dexcom
- WST vs MMM 3M
- WST vs PODD Insulet
- WST vs RMD ResMed
- WST vs SOLV Solventum
- WST vs SYK Stryker